Columbia University

Technology Ventures

The Future of Immuno-Oncology: Combination Treatments

November 14, 2017
Norman Selby, Sophie Opdyke, Umer Raffat, Peter Bach,
UJA Conference Center
130 East 59th Street, Room 712
New York, NY

Overview: Immuno-oncology treatments have provided renewed hope to cancer patients. Combination treatments bring the promise of increased efficacy with manageable side effects. Come hear from experts about what the future may bring. There will be opportunity to network with fellow alumni during this event. Light refreshments will be provided. Registration required, $20 HBSHAA members, $40 non-members.

Sophie Opdyke, VP& Immuno-Oncology Lead - Global Commercial Development, Pfizer. Responsible for developing and directing Pfizer’s strategies in the Immuno-Oncology area, leading commercial activities from pre-POC and pipeline assets in collaboration with R&D and championing BD opportunities in the field.
Umer Raffat, Senior Managing Director, Evercore ISI, M.S. International Health Economics, Harvard University. Covers large cap therapeutics, including Biotech, Pharmaceuticals-major and Specialty Pharmaceuticals. Ranked #1 in Institutional Investor’s Specialty Pharmaceuticals category for the last two years.
Peter Bach, Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes, B.A., Harvard University. Physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients as a critical component.
Norman Selby, MBA 1978, Chairman, Real Endpoints and PAIGE.AI, Board of Trustees at Memorial Sloan Kettering, former Senior Partner at McKinsey. Norman Selby has spent over 30 years in the healthcare world in a variety of consulting, managerial, investor and Board roles. He is also on the Board of Directors of Infinity Pharmaceuticals (INFI), a leading public biotech oncology company, Merz Group GmbH, a global specialty pharma company based in Frankfurt, Germany, and Metamark Genetics, a leading prostate cancer diagnostics company.
Contact Information:
Lisa Sakai Plimpton, MBA 2013
HBSHAA Regional Director
Cristina Okuyama, MBA 2006
HBSHAA Regional Director
Jadelind Wong, MBA 2012
HBSHAA Regional Director